1-10 of 10
Ronald W. Takvorian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1867.
https://doi.org/10.1182/blood-2024-205697
Published: 2024
Journal Articles

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Matthew S. Davids, Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar, Leyla Shune, Mohammad Omaira, Caron Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer L. Crombie, Ann S. LaCasce, Jon E. Arnason, Ephraim Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, David C. Fisher, Jennifer R Brown
Journal: Blood
Blood (2021) 138 (Supplement 1): 640.
https://doi.org/10.1182/blood-2021-146624
Published: 2021
Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3990.
https://doi.org/10.1182/blood-2019-126920
Published: 2019
Journal Articles

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Clinical Trials & Observations
Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ephraim P. Hochberg, Celeste M. Bello
Journal: Blood
Blood (2019) 134 (7): 606–613.
https://doi.org/10.1182/blood.2019001272
Published: 2019
Includes: Supplemental data
Journal Articles

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Clinical Trials & Observations
Philipp Karschnia, Justin T. Jordan, Deborah A. Forst, Isabel C. Arrillaga-Romany, Tracy T. Batchelor, Joachim M. Baehring, Nathan F. Clement, L. Nicolas Gonzalez Castro, Aline Herlopian, Marcela V. Maus, Michaela H. Schwaiblmair, Jacob D. Soumerai, Ronald W. Takvorian, Ephraim P. Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Matthew J. Frigault, Jorg Dietrich
Journal: Blood
Blood (2019) 133 (20): 2212–2221.
https://doi.org/10.1182/blood-2018-12-893396
Published: 2019
Journal Articles

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, MD MMSc, Robert A. Redd, MS, Jeffrey A. Barnes, MD PhD, Elizabeth Bengtson, MD, Ronald W. Takvorian, MD, Lubomir Sokol, MD PhD, Frederick Lansigan, MD, Philippe Armand, MD PhD, Bijal D. Shah, MD, Eric D Jacobsen, MD, Donna S Neuberg, ScD, Ann S. LaCasce, MD MSc, Celeste M. Bello, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2018-99-115173
Published: 2018
Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 496.
https://doi.org/10.1182/blood.V130.Suppl_1.496.496
Published: 2017
Journal Articles

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Clinical Trials & Observations
David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson, for Cancer and Leukemia Group B
Journal: Blood
Blood (2011) 117 (20): 5314–5320.
https://doi.org/10.1182/blood-2010-10-314260
Published: 2011
Journal Articles

Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.

Jennifer R. Brown, MD, PhD, Iryna Rastarhuyeva, MD, Jyothi Jagannathan, MD, Kristen Stevenson, MS, Donna Neuberg, ScD, Yulia Melenevsky, MD, Kimberly S. Phillips, BA, Jennifer C. Clark, MA, Ronald W. Takvorian, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Annick D. Van den Abbeele, MD
Journal: Blood
Blood (2007) 110 (11): 2331.
https://doi.org/10.1182/blood.V110.11.2331.2331
Published: 2007
Journal Articles

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Jennifer R. Brown, MD, PhD, Jonathan Friedberg, MD, Yang Feng, MS, Kimberly Phillips, BA, Jennifer C. Clark, MA, Paola dal Cin, PhD, Robin Joyce, MD, David C. Fisher, MD, Richard I. Fisher, MD, Ronald W. Takvorian, MD, Jane Liesveld, MD, Diana Marquis, BS, Donna Neuberg, ScD, Arnold S. Freedman, MD
Journal: Blood
Blood (2007) 110 (11): 1358.
https://doi.org/10.1182/blood.V110.11.1358.1358
Published: 2007